NCT00112957View on ClinicalTrials.gov

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
BIOLOGICAL

rV-NY-ESO-1 vaccine

Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.

BIOLOGICAL

rF-NY-ESO-1 vaccine

Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
collaborator

Roswell Park Cancer Institute

OTHER

lead

Ludwig Institute for Cancer Research

OTHER